Kringle Pharma, Inc.

Quick facts

Phase 3 pipeline

• KP-100IT · Immunology
  KP-100IT is a small molecule that targets the S1P1 receptor.
• KP-100LI · Diabetes
  KP-100LI is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kringle Pharma, Inc. portfolio CI brief
• Kringle Pharma, Inc. pipeline updates RSS